Iovera

What Iovera does

Iovera, legally Pacira CryoTech, Inc., is a medical device company headquartered in Tampa, Florida, operating as a wholly owned subsidiary of Pacira BioSciences, Inc. Its sole commercial product is the iovera° system, an FDA-cleared cryoneurolysis device that applies extreme cold to peripheral nerve tissue to temporarily block pain signal transmission, providing drug-free pain relief for up to 90 days. The system is cleared for osteoarthritis knee pain, post-surgical knee replacement pain, and additional peripheral pain indications including hip, shoulder, foot and ankle, spine, rib fracture, and mastectomy-related pain.

The iovera° system is administered by healthcare professionals and can be delivered in hospital outpatient departments, ambulatory surgery centers, or physician offices. The company's go-to-market is sales-led and dual-sided: a consumer-facing website (iovera.com) with educational content and a 'Find a Doctor' locator drives patient demand, while a dedicated healthcare professional portal (ioverapro.com) enables clinical adoption. Revenue is generated through device and treatment-system sales to providers and facilities; pricing is not publicly disclosed and is determined downstream by providers and insurance coverage.

Iovera was founded in 2010 and currently reports a headcount of 501-1000 employees. Its distribution is concentrated in the United States, with no global footprint claimed. The company operates without independent venture capital backing disclosed, instead leveraging its parent company's commercial and corporate infrastructure. There is no evidence of standalone funding rounds, mergers, acquisitions, or leadership changes in the source material.

Name

Iovera

Legal name

Pacira CryoTech, Inc.

Website

https://iovera.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

10,001+ employees

Short description

Iovera, a wholly owned subsidiary of Pacira BioSciences, manufactures the FDA-cleared iovera° cryoneurolysis system that provides drug-free, up-to-90-day peripheral nerve pain relief for osteoarthritis, post-surgical, and other pain patients treated by healthcare providers.

Ownership category

akta.pro rank

Product category

Medical Equipment Manufacturing

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro industry

PRIMARYHLAFABAH

Pain Management Clinics (Interventional & Medical)

Healthcare & Life Sciences/Healthcare Providers & Systems/Ambulatory & Outpatient Care Centers

Keywords

• Cryoneurolysis medical device
• Non-opioid pain relief
• Peripheral nerve blocking
• FDA-cleared cryotherapy
• Pain management equipment

Headquarters

HQ city

Brisbane

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Device and Treatment System Sales: The iovera° system is a medical device used by healthcare providers to deliver cryoneurolysis treatments. Revenue is generated through device sales to hospitals, ambulatory surgery centers, and physician offices, along with associated treatment procedures.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Iovera manufactures and commercializes the iovera° cryoneurolysis system, an FDA-cleared medical device that applies freezing cold to peripheral nerve tissue to temporarily block pain signals, providing drug-free, non-opioid pain relief for up to 90 days. The system is administered by healthcare professionals in hospitals, ambulatory surgery centers, and physician offices, primarily for osteoarthritis knee pain, post-knee replacement pain, and other peripheral pain conditions including hip, shoulder, foot/ankle, spine, rib fracture, and mastectomy-related pain.

Product overview

Iovera offers the iovera° cryoneurolysis system, a single FDA-cleared medical device that uses extreme cold to temporarily stop peripheral nerves from sending pain signals. The iovera° device provides immediate, drug-free pain relief for up to 90 days and can be administered in hospital outpatient departments, ambulatory surgery centers, or physician offices. The system is primarily used to treat osteoarthritis knee pain, pain following knee replacement surgery, and pain in the hip, shoulder, foot, ankle, spine, as well as pain related to rib fractures and mastectomy procedures.

Differentiator

Problem solved

Functional benefit

Products and services

• iovera° Cryoneurolysis System FDA-cleared medical device and treatment system that applies extreme cold to peripheral nerve tissue to temporarily block pain signals, providing immediate, drug-free pain relief for up to 90 days. Indicated for osteoarthritis knee pain, post-surgical pain following knee replacement, and other peripheral pain conditions including hip, shoulder, foot/ankle, spine, rib fracture, and mastectomy-related pain. Administered by healthcare professionals in hospital outpatient departments, ambulatory surgery centers, or physician offices.

Quantifiable outcome

• Up to 90 days of pain relief in studies using iovera° for knee pain
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves5 records

Expansion highlights3 records

Broad incumbents

• Medtronic: Medtronic is one of the largest medtech incumbents with a meaningful pain therapies portfolio (including spinal cord stimulation and targeted drug delivery). It is comparable to iovera° because both compete for interventional pain management budgets across hospitals and pain specialists, though Medtronic addresses a much broader indication set.
• Boston Scientific: Boston Scientific is a leading neuromodulation and pain management incumbent with spinal cord stimulation and radiofrequency ablation systems. It competes with iovera° for share of interventional pain treatment channels and physician mindshare among pain specialists and orthopedic surgeons.
• Abbott: Abbott competes directly in interventional pain through its neuromodulation portfolio, including DRG stimulation and spinal cord stimulation. It is comparable to iovera° because both target chronic peripheral and joint pain with device-based, non-pharmacologic approaches across hospitals and ambulatory sites.
• Stryker: Stryker operates broadly across surgical and pain management devices used in hospital and ASC settings, including interventional pain offerings. Comparable to iovera° because both sell capital equipment and disposables into orthopedic and pain-focused outpatient channels.

Direct peers

• Avanos Medical: Avanos markets the COOLIEF cryoablation system, which uses cold-based neurolysis to relieve chronic knee pain — directly overlapping iovera°'s osteoarthritis knee indication. It is the closest comparable cryoneurolysis competitor in the same clinical use case and channel.
• Nevro: Nevro is a pure-play neuromodulation company focused on high-frequency spinal cord stimulation for chronic pain. It competes with iovera° for interventional pain procedure share among pain specialists and orthopedic surgeons managing chronic and post-surgical pain.

Emerging players

• Relievant Medsystems: Relievant Medsystems markets the Intracept procedure, a minimally invasive nerve ablation therapy targeting vertebrogenic low back pain. It overlaps with iovera° as an interventional, nerve-targeting, non-opioid alternative for chronic musculoskeletal pain treated in outpatient settings.
• Vertos Medical: Vertos Medical offers the mild Procedure for lumbar spinal stenosis, a percutaneous nerve-targeting decompression therapy. It is comparable to iovera° as a minimally invasive, non-opioid, interventional pain treatment delivered in outpatient settings by pain specialists.
• Saluda Medical: Saluda Medical develops closed-loop spinal cord stimulation systems for chronic pain. It is comparable to iovera° as a non-opioid, device-based interventional approach targeting chronic pain patients managed by pain specialists in outpatient settings.

Regional players

• AtriCure: AtriCure specializes in cryotherapy-based surgical ablation for cardiac arrhythmias. While its clinical focus is different, the underlying cryothermal ablation technology is comparable to iovera°'s cryoneurolysis platform and represents a related cold-energy medical device approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@ioveraofficial
• Facebookfacebook.com/iovera.us
• LinkedInlinkedin.com/company/iovera-usa
• Instagraminstagram.com/iovera.us
• Xx.com/iovera

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds7 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iovera